Know Labs’ RF glucose sensor achieves 11.1% MARD in first venous-blood study

USBC, Inc.

Overall MARD of 11.1±2.1% in test dataset; similar accuracy in normoglycemic (11.0%) and hyperglycemic (11.5%) ranges.
First study using venous blood as reference in participants with prediabetes and Type 2 diabetes.
Study involved 21 three-hour sessions with 75g OGTT; 520 paired values for training, 130 for test.
Clinical trial completed (up to 100 participants, Sep 2023–Feb 2024); company plans large-scale external trials in 2024.
Dr. Virend K. Somers of Mayo Clinic is co-investigator; results presented at ATTD conference in Florence.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.